A multiple sclerosis disease-modifying drug treatment for motor neurone disease (MND) is becoming available on the PBS at a much lower patient price, reducing the cost from more than $28,000 per script to $25 for eligible patients.
Both outlets report that the change follows the drug’s listing on the Pharmaceutical Benefits Scheme (PBS), which determines the subsidised medicines available to Australians. The reporting highlights that the $25 co-payment replaces the previously high out-of-pocket cost for scripts.
Both sources also frame the development as significant in connection with Neale Daniher, linking the PBS listing and pricing change to his legacy and advocacy. Across the articles, the core points are the same: the PBS listing, the dramatic reduction in script cost, and the resulting lower expense for qualifying MND patients. The two reports do not introduce differing factual claims about timing, eligibility criteria, or clinical details of the drug beyond the price change and context.
